Althea Technologies Gains National Spotlight as Wall Street Journal Top Workplace Finalist
10.9.2007 Althea Technologies Gains National Spotlight as Wall Street Journal Top Workplace Finalist
SAN DIEGO – October 9, 2007 -- Althea Technologies, Inc., a leading provider of innovative technologies and services for pharmaceutical development and manufacturing, announced today that it is a finalist for the Top Small Workplaces Award sponsored by The Wall Street Journal and Winning Work Places. The Wall Street Journal is the nation’s premier business publication with a daily readership of 2 million and Winning Work Places is a not-for-profit providing consulting, training and information to help small and mid-sized organizations. Althea was one of thirty-five finalists featured at the awards dinner in Chicago, IL on October, 3, 2007 selected from companies nationwide.
The Top Small Workplaces Award seeks to identify exceptional small companies in its first annual ranking of the Top Small Workplaces. Through a national search the Wall Street Journal and Winning Workplaces has identified employers that foster teamwork, flexibility, high productivity and innovation while also treating their employees with respect, providing opportunities for professional growth and advancement, and providing benefits, both traditional and nontraditional, that make the employee experience better.
President and Co-CEO of Althea, Dr. Magda Marquet, added, “Just being a finalist in this national contest is an incredible milestone for us. Althea has been growing at an extraordinary pace and it is rewarding to see our hard work in preserving the special culture of the company recognized on the national stage by two prestigious organizations. This achievement was only possible because of our incredible employees, and to them I say – Thank You.”
About Althea Technologies, Inc.
Althea Technologies, a leading San Diego-based pharmaceutical services firm, provides critical manufacturing and development services that support researchers worldwide in their advancement of novel therapies and efforts to apply new genomic information. Althea’s services include cGMP contract manufacturing of recombinant proteins, DNA-based therapeutics and vaccines, aseptic filling, and gene quantification using real-time PCR and gene expression analysis under GLP conditions. Additionally, Althea has introduced new services and technologies for the identification and development of genetic biomarkers with innovative programs such as the company’s proprietary Express Pathway℠.